Technical Analysis for IMPL - Impel NeuroPharma, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.04 | -27.27% | -0.02 |
IMPL closed down 27.27 percent on Wednesday, December 20, 2023, on 59 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 22
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
New 52 Week Low | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
New 52 Week Closing Low | Bearish | -27.27% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/22/2024
Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Parkinson's Disease Autism Spectrum Disorder Migraine Central Nervous System Disease Prodrugs Treatment Of Migraine Combination Drugs Carbidopa L Dopa
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Parkinson's Disease Autism Spectrum Disorder Migraine Central Nervous System Disease Prodrugs Treatment Of Migraine Combination Drugs Carbidopa L Dopa
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.2 |
52 Week Low | 0.0212 |
Average Volume | 1,228,273 |
200-Day Moving Average | 0.97 |
50-Day Moving Average | 0.34 |
20-Day Moving Average | 0.41 |
10-Day Moving Average | 0.28 |
Average True Range | 0.11 |
RSI (14) | 31.51 |
ADX | 32.78 |
+DI | 21.91 |
-DI | 29.00 |
Chandelier Exit (Long, 3 ATRs) | 0.72 |
Chandelier Exit (Short, 3 ATRs) | 0.36 |
Upper Bollinger Bands | 0.82 |
Lower Bollinger Band | 0.01 |
Percent B (%b) | 0.04 |
BandWidth | 196.79 |
MACD Line | -0.07 |
MACD Signal Line | -0.02 |
MACD Histogram | -0.0497 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.08 | ||||
Resistance 3 (R3) | 0.08 | 0.07 | 0.08 | ||
Resistance 2 (R2) | 0.07 | 0.05 | 0.07 | 0.07 | |
Resistance 1 (R1) | 0.05 | 0.05 | 0.05 | 0.05 | 0.07 |
Pivot Point | 0.04 | 0.04 | 0.03 | 0.04 | 0.04 |
Support 1 (S1) | 0.02 | 0.03 | 0.02 | 0.03 | 0.01 |
Support 2 (S2) | 0.01 | 0.02 | 0.01 | 0.01 | |
Support 3 (S3) | 0.00 | 0.01 | 0.00 | ||
Support 4 (S4) | 0.00 |